Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for acute myeloid leukemia.

Joseph G Jurcic1

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 458, New York, NY 10021, USA. jurcicj@mskcc.org

Current Oncology Reports
|August 11, 2005
PubMed
Summary

Immunotherapy offers new hope for acute myeloid leukemia (AML) treatment. Targeted therapies like antibodies and radioimmunotherapy show promise in eliminating cancer cells and residual disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.

Blood neoplasia·2026
Same author

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Blood advances·2026
Same author

Imatinib-induced rhabdomyolysis: A case report.

Leukemia research reports·2026
Same author

Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.

The Journal of allergy and clinical immunology·2025
Same author

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

Cancer cell·2025
Same author

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Immunotherapeutic strategies are integral to modern cancer treatment.
  • Chimeric and humanized antibodies show efficacy against various tumors.
  • Specific antibodies target cell surface antigens for therapeutic intervention.

Purpose of the Study:

  • To review current immunotherapeutic strategies for acute myeloid leukemia (AML).
  • To highlight the potential of novel approaches in AML treatment.
  • To discuss the role of targeted therapies in managing minimal residual disease.

Main Methods:

  • Review of existing literature on immunotherapies for AML.
  • Analysis of antibody-based therapies, including radioimmunotherapy and targeted chemotherapy.
  • Exploration of T-cell based immunotherapeutic concepts.

Main Results:

  • Humanized anti-CD33 antibody (HuM195) shows activity against minimal residual disease in acute promyelocytic leukemia.
  • Radioimmunotherapy with beta-particle emitters targeting CD33, CD45, and CD66 can intensify antileukemic therapy.
  • Alpha-particle immunotherapy offers selective tumor cell kill.
  • Gemtuzumab ozogamicin (anti-CD33-calicheamicin) has induced remissions in relapsed AML and shows promise in combination therapy.
  • T-cell recognition of peptide-MHC complexes presents a potential therapeutic avenue.

Conclusions:

  • Immunotherapy, including antibody-based and radioimmunotherapy, offers diverse strategies for AML treatment.
  • Targeted agents like gemtuzumab ozogamicin and novel T-cell approaches hold significant promise for improving patient outcomes.
  • Further research into these immunotherapeutic modalities is warranted for optimizing AML management.

Related Experiment Videos